Fewer Than 10 of Practising Doctors Have Been Educated in Molecular Medicine Thus Adoption of Molecular Tests in Clinical Pra



Research and Markets (http://www.researchandmarkets.com/reports/c41939) has announced the addition of Innovations in Diagnostics: Next Generation Molecular and Point-of-Care Diagnostics Driving Personalized Healthcare to their offering.

The global diagnostics market is undergoing radical change; novel technologies driven by miniaturization and advances in genomics will enhance the role of diagnostics in the healthcare market, allowing more tests to be performed at the point-of-care and facilitating the shift towards personalized medicine. 's8220;Innovation in Diagnostics's8221; examines the advances in the rapidly growing field of molecular technologies that are enabling personalized healthcare to move into mainstream medicine.

New opportunities in infectious disease testing, molecular oncology and pharmacogenomics are explored in detail, enabling you to understand the forces that are driving in vitro diagnostics (IVDs) into centre stage of the healthcare arena. Understand the changing relationship between IVD companies and the pharmaceutical industry, assess the convergence of IVDs and medical imaging, and develop an understanding of new technologies that will influence diagnostic product development and drug development programs.

Key Findings of this Report:

- Consolidation in the IVD industry is highlighted by the dominance of the leading 15 companies, which account for almost 90% of the global IVD market. Roche is the major player with a 20% market share.
- Fewer than 10% of practising doctors have been educated in molecular medicine, thus adoption of molecular tests in clinical practice will demand training and educational materials from the IVD industry.
- The full clinical potential of molecular diagnostics has yet to be realized. Clinical applications beyond the field of infectious disease testing will make this the fastest-growing market segment in the next decade.
- IVD companies devote 35% of revenues to R&D, significantly more than the pharmaceutical industry, underlining the driving force of technology innovation which is forcing the pace of change among players in the industry .
- Genotyping of known biomarkers will reduce drug toxicity problems and contribute to better dosing regimens, offering the potential for fewer drug withdrawals resulting from safety concerns.

Key Questions Answered in this Report:

- What will the IVD market be worth by the end of the decade
- Which market segments will drive IVD market growth
- Which new technologies will reach the market in the next 2-3 years
- How is technology innovation impacting the dynamics and ownership of the IVD industry
- What are the key challenges in gaining acceptance of new technologies by users, payers and regulators
- How is technology innovation facilitating the transition of personalized medicine into standard healthcare practice
- How will IVD technology developments impact labelling of existing and future drugs

Top 5 Reasons To Order Your Copy Today:

- Discover the IVD sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success.
- Evaluate the competitive dynamics of the IVD market and understand the changing relationship between IVD companies and the pharmaceutical industry.
- Identify the key players in the IVD market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players.
- Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users.
- Understand the factors driving growth of the point-of-care market, which represents over 30% of global IVD sales.

Chapter Titles Include:-
Chapter 1 Introduction to diagnostics
Chapter 2 Challenges and opportunities in diagnostic innovation
Chapter 3 Molecular technology innovations
Chapter 4 Innovation in infectious disease diagnostics
Chapter 5 Personalized medicine
Chapter 6 Point-of-care testing
Chapter 7 Competitive landscape
Chapter 8 Appendix

List of Figures
List of Tables

The Companies Mentioned inside this report include:

- Abbott
- Affymetrix
- Becton Dickinson
- Dx divisions
- Gen-Probe
- Inverness Medical Innovations (IMI)
- Nanogen
- Orion Genomics's8217;
- Roche Diagnostics

For more information visit http://www.researchandmarkets.com/reports/c41939

Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 4100 980





Fewer Than 10 of Practising Doctors Have Been Educated in Molecular Medicine Thus Adoption of Molecular Tests in Clinical Pra